Drugs that contain Bempedoic Acid; Ezetimibe
1. List of Nexlizet drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7335799 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9000041 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(10 months from now) | |
| US10941095 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(10 months from now) | |
| US10118881 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(10 months from now) | |
| US8497301 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(10 months from now) | |
| US9624152 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(10 months from now) | |
| US10912751 | ESPERION THERAPS INC | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
Mar, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 21, 2025 |
| New Product (NP) | Feb 26, 2023 |
NCE-1 date: February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; A method of treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease by decreasing the level of ldl-c using a fixed dose combination of 180 mg bempedoic acid and 10 mg ezetimibe
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic